Dynamic changes of platelet count in patients with atrial fibrillation treated with oral anticoagulants and its correlation with prognosis such as bleeding

Objective: To investigate the dynamic changes in platelet count in patients with atrial fibrillation treated with oral anticoagulants an d the prognostic correlation with bleeding and other conditions. Methods: A total of 72 patients with post-atrial fibrillation who were treated in our hospital from August 2019 to March 2022 were selected and divided into two categories according to different healing methods, including 35 cases in the rivaroxaban category, 37 cases in the dabigatran etexilate category, and all The patients consented to this study. The platelet count, activation function index, coagulation function and the incidence of bleeding were compared between the t wo categories after healing with different methods, so as to analyze the dynamic changes of platelet count in patients with atrial fibrillation treated with oral anticoagulants and their correlation with prognosis such as bleeding. Results: None notablely difference in platelet count between the two categories before healing (P>0.05), and the platelet count decreased in both categories after 3 d, 7 d, 14 d, 21 d and 28 d of healing, but the decrease in the dabigatranate category was less than that in the rivaroxaban category (P<0.05). CD62P levels decreased in both categories, but the decrease in the dabigatranate category was less than that in the rivaroxaban category (P < 0.05); PAC-1 levels did not differ notablelyly between the two categories before healing (P > 0.05), and decreased in both categories after 3 d, 7 d, 14 d, 21 d and 28 d of healing, but the decrease in the dabigatranate category was less than that in the rivaroxaban category (P < 0.05). None notablely difference in D-D, PT, INR and APTT between the two categories before healing (P>0.05). None notablely difference in the healing efficiency between the two categories (P>0.05). Conclusion: In the anticoagulation healing of atrial fibrillation, oral administration of dabigatran etexilate and rivaroxaban can cause changes in platelet count. Trenester. At the same time, the blood rate after dabigatran etexilate healing was lower than that of rivaroxaban, which was related to the small changes in platelet count and coagulation function.